Fukuda Denshi (6960) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
9 Sep, 2025Executive summary
Net sales for the six months ended September 30, 2024, were ¥64,314 million, down 3.3% year-over-year.
Operating profit decreased 23.6% year-over-year to ¥10,654 million.
Ordinary profit fell 20.1% year-over-year to ¥11,262 million; profit attributable to owners of parent dropped 21.4% to ¥7,706 million.
Comprehensive income declined 47.6% year-over-year to ¥6,014 million.
Financial highlights
Earnings per share for the period were ¥267.34, down from ¥324.32 year-over-year.
Total assets as of September 30, 2024, were ¥204,776 million, a decrease of ¥4,288 million from March 31, 2024.
Net assets increased to ¥171,975 million, up ¥2,967 million from the previous fiscal year-end.
Shareholders’ equity ratio improved to 84.0% from 80.8% at the previous year-end.
Outlook and guidance
Full-year forecast remains unchanged: net sales of ¥135,000 million (down 3.8%), operating profit of ¥23,000 million (down 14.8%), and profit attributable to owners of parent of ¥16,500 million (down 11.7%).
Earnings per share for the full year forecasted at ¥572.37.
No revisions to the business forecast as of this announcement.
Latest events from Fukuda Denshi
- Slight YoY profit decline offset by strong comprehensive income and stable full-year outlook.6960
Q3 20265 Feb 2026 - Net sales up 0.8% and operating profit steady, with segment shifts and stable full-year outlook.6960
Q2 202612 Nov 2025 - Sales rose 4% year-over-year, but profits declined; full-year guidance and dividends unchanged.6960
Q1 20259 Sep 2025 - Profits declined despite stable sales, with mixed segment performance and steady full-year outlook.6960
Q3 20259 Sep 2025 - Slight declines in sales and profit, with FY2026 guidance indicating further contraction.6960
Q4 20259 Sep 2025 - Profits declined despite stable sales; medical treatment and consumables segments showed growth.6960
Q1 20269 Sep 2025